Overview of the prospective randomized evaluation of the vascular effects of Norvasc (amlodipine) trial: PREVENT.

Paper

Overview of the prospective randomized evaluation of the vascular effects of Norvasc (amlodipine) trial: PREVENT.

Published 2000 · G. Mancini

The Canadian journal of cardiology

4

Citations

1

Influential Citations

Semantic Scholar

Abstract

The Prospective Randomized Evaluation of the Vascular Effects of Norvase (amlodipine) Trial (PREVENT) was designed specifically to assess if amlodipine can be shown to inhibit angiographic progression of lesions 30% or less diameter stenosis. A carotid ultrasound substudy was also undertaken. The antiatherosclerotic effects were discordant in that minor coronary lesions were not affected, whereas carotid intima-media thickness showed significantly less progression in the amlodipine-treated patients. Moreover, significant cardiac events, particularly admissions to hospital for unstable angina and intervention, were significantly reduced in the amlodipine-treated patients. This brief report provides an overview and assessment of the implications of these findings.

Study Snapshot

Key takeawayAmlodipine reduces carotid intima-media thickness progression and significantly reduces unstable angina hospital admissions, but does not affect minor coronary lesions.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Overview of the prospective randomized evaluation of the vascular effects of Norvasc (amlodipine) trial: PREVENT.

References

Citations